Sven Wind
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Immunology top 5%
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Papers in
- Oncology 24
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 6
- Colorectal Cancer Treatments and Studies 6
-
- Lung Cancer Treatments and Mutations 16
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 4
- Co-authors
- Harald Schmidt (3 shared papers)Rudi Busse (1 shared paper)Ralf P. Brandes (1 shared paper)Katrin Schröder (1 shared paper)Eduardo Barbosa‐Sicard (1 shared paper)Peter Stopfer (8 shared papers)Matthias Freiwald (3 shared papers)Thomas Ebner (2 shared papers)
- Journals
- Annals of Oncology (4 papers)Journal of Clinical Oncology (3 papers)Clinical Pharmacokinetics (3 papers)Molecular Pharmaceutics (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)
- Partner nations
- GermanyUnited StatesCanada
In The Last Decade
Sven Wind
39 papers receiving 2.1k citations
Sven Wind's Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 616
- Immunology 462
- Physiology 541
- Pulmonary and Respiratory Medicine 632
- Genetics 187
Countries citing papers authored by Sven Wind
This map shows the geographic impact of Sven Wind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Wind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Wind more than expected).
Fields of papers citing papers by Sven Wind
This network shows the impact of papers produced by Sven Wind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Wind. The network helps show where Sven Wind may publish in the future.
Co-authors
The 25 scholars most cited alongside Sven Wind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant Hit paper breakdown → | 2007 | 637 |
| 2 | 2010 | 205 | |
| 3 | 2012 | 154 | |
| 4 | 2010 | 148 | |
| 5 | 2016 | 146 | |
| 6 | 2019 | 138 | |
| 7 | 2014 | 134 | |
| 8 | 2013 | 76 | |
| 9 | 2012 | 71 | |
| 10 | 2012 | 65 | |
| 11 | 2014 | 54 | |
| 12 | 2014 | 42 | |
| 13 | 2018 | 33 | |
| 14 | 2014 | 32 | |
| 15 | 2013 | 31 | |
| 16 | 2017 | 28 | |
| 17 | 2018 | 26 | |
| 18 | 2018 | 20 | |
| 19 | 2016 | 17 | |
| 20 | 2011 | 12 |
About Sven Wind
Sven Wind is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Hematology and Physiology, having authored 39 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), HER2/EGFR in Cancer Research (14 papers), Chronic Myeloid Leukemia Treatments (7 papers), Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). The work is most often cited by research in Oncology (616 citations), Immunology (462 citations), Physiology (541 citations), Pulmonary and Respiratory Medicine (632 citations) and Genetics (187 citations). Sven Wind has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Harald Schmidt, Rudi Busse, Ralf P. Brandes, Katrin Schröder, Eduardo Barbosa‐Sicard, Peter Stopfer, Matthias Freiwald, Thomas Ebner, Knut Beuerlein and Kirstin Wingler. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Pharmacokinetics, Molecular Pharmaceutics and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.